2023-11-15T23:01:23-06:00 2022-12-31 873231666 PKF O'CONNOR DAVIES ADVISORY LLC 245 PARK AVENUE 12TH FLOOR NEW YORK NY 10167 990 2022-01-01 133859563 THE ZACHARY & ELIZABETH M FISHER CENTER FOR ALZHEIMER'S RESEARCH FOUNDATION ZACH 2129151328 750 LEXINGTON AVENUE 2400 NEW YORK NY 10022 BARRY R SLOANE CHAIRMAN & TREASURER 2129151328 2023-11-15 1 BARRY SLOANE 999009999 1 EVA MRUK P00543254 2122862600 2023-11-14 3 AAL1 IAL1 2022 2023-04-26 12:10:37Z ALZHEIMER'S RESEARCH FOUNDATIONFISHER CENTER BARRY R SLOANE 750 LEXINGTON AVENUE 2400 NEW YORK NY 10022 17802240 0 X WWW.ALZINFO.ORG X 1995 NY TO FUND RESEARCH INTO THE CAUSE, CARE, AND CURE OF ALZHEIMER'S DISEASE AT THE ZACHARY AND ELIZABETH M. FISHER CENTER FOR RESEARCH ON ALZHEIMER'S DISEASE AT THE ROCKEFELLER UNIVERSITY IN NEW YORK THAT WAS UNDER THE DIRECTION OF NOBEL LAUREATE DR. PAUL GREENGARD WHOSE FINDINGS HAVE BEEN THE BASIS FOR MUCH OF TODAY'S ALZHEIMER'S INVESTIGATIONS. 10 10 7 10 0 0 8297600 7384683 2684 1215 1718386 -301890 2643 0 10021313 7084008 13302276 10122943 0 0 664391 921566 0 0 484116 1125382 1389874 15092049 12434383 -5070736 -5350375 40802431 30196268 10335943 9721915 30466488 20474353 X THE ZACHARY AND ELIZABETH M. FISHER CENTER FOR ALZHEIMER'S RESEARCH FOUNDATION IS DEDICATED TO ATTACKING THE SCOURGE OF ALZHEIMER'S DISEASE THROUGH A 3-PRONGED ASSAULT FOCUSED ON UNDERSTANDING THE CAUSE OF ALZHEIMER'S DISEASE (AD), IMPROVING THE CARE OF PEOPLE LIVING WITH THE DISEASE TO ENHANCE THEIR QUALITY OF LIFE AND THAT OF THEIR CAREGIVERS AND FAMILIES, AND FINDING A CURE. 0 0 5440524 5000000 0 FISHER DRUG DISCOVERY RESOURCE CENTER:A GRANT WAS MADE TO THE ROCKEFELLER UNIVERSITY FOR THE FISHER DRUG DISCOVERY RESOURCE CENTER LOCATED AT THE ROCKEFELLER UNIVERSITY'S BRONK LABORATORY BUILDING TO HELP DRIVE TRANSFORMATIONAL SCIENCE AND FUEL THE DEVELOPMENT OF INNOVATIVE THERAPEUTICS WITH HIGH-THROUGHPUT AND SPECTROSCOPY RESOURCE CENTER (HTSRC). HIGH-THROUGHPUT SCREENING AND OTHER TECHNOLOGIES ENABLE THE IDENTIFICATION OF THERAPEUTIC TARGETS FOR POTENTIAL PREVENTIONS OR EFFECTIVE TREATMENTS OF VIRTUALLY ANY HUMAN DISEASE. 3808367 3500000 0 THE ZACHARY AND ELIZABETH M. FISHER CENTER FOR RESEARCH ON ALZHEIMER'S DISEASE (THE FISHER CENTER LAB):THE PRINCIPAL ACTIVITY OF THE FISHER CENTER FOR ALZHEIMER'S RESEARCH FOUNDATION IS TO PROVIDE FUNDING TO THE FISHER CENTER LAB AT THE ROCKEFELLER UNIVERSITY, ONE OF THE LARGEST AND MOST MODERN FACILITIES IN THE WORLD DEDICATED TO SOLVING THE PUZZLE OF ALZHEIMER'S DISEASE. CURRENTLY LED BY NEWLY APPOINTED DIRECTOR, DR. NATHANIEL HEINTZ, THE JAMES AND MARILYN SIMONS PROFESSOR AT THE ROCKEFELLER UNIVERSITY. THE FISHER CENTER HAS PROVIDED RESEARCHERS AROUND THE GLOBE WITH A CONCEPTUAL FRAMEWORK FOR UNDERSTANDING THE DISEASE PROCESS AND CONTINUES TO BE AT THE FOREFRONT OF ONE DAY FINDING A CURE FOR ALZHEIMER'S DISEASE (AD). 1088105 1000000 0 4C. CASANOVA SARS-COV-2 INFECTION:A GRANT WAS MADE TO DR. CASANOVA'S RESEARCH ON UNDERSTANDING THE LIFE-THREATENING MANIFESTATION OF SARS-COV-2 INFECTION. HIS LABORATORY DISCOVERED THE HUMAN DETERMINANTS OF LIFE-THREATENING COVID-19 PNEUMONIA IN AT LEAST 20% OF PATIENTS, WITH INBORN ERRORS OF AND AUTO-ANTIBODIES TO TYPE I INTERFERONS. SARS-COV-2 WILL CONTINUE TO INFECT UNVACCINATED INDIVIDUALS FOR THE FORESEEABLE FUTURE AND WILL INCREASINGLY INFECT VACCINATED INDIVIDUALS AS IMMUNITY WANES OR AS VIRAL VARIANTS APPEAR THAT EVADE EXISTING VACCINE TARGETS. THE EMERGENCE OF VIRAL VARIANTS WITH GREATER FITNESS/TRANSMISSIBILITY AND IMMUNE EVASION POTENTIAL EXACERBATES THE THREAT TO HUMAN HEALTH, AS TRAGICALLY ILLUSTRATED WITH LIFE-THREATENING "BREAKTHROUGH CASES". THEIR APPROACH IS TO COUNTERATTACK THE VIRAL CHALLENGE USING SYNERGISTIC GENOMIC AND IMMUNOLOGIC APPROACHES. THEIR STUDIES INCLUDE DEEP ANALYSIS OF INTER-INDIVIDUAL GENETIC VARIABILITY, BUILDING ON DISCOVERY OF GERMLINE HUMAN GENETIC VARIANTS AND THEIR AUTOIMMUNE PHENOCOPIES PREDISPOSING TO POOR OUTCOME. 262943 262943 0 THE ROCKEFELLER UNIVERSITY GREENGARD PROFESSORSHIP IN NEUROSCIENCE:THE ORGANIZATION PROVIDED FUNDING FOR THE PAUL GREENGARD PROFESSORSHIP IN NEUROSCIENCE AT ROCKEFELLER UNIVERSITY IN HONOR OF THE LATE NOBEL LAUREATE AND HIS 35 YEAR TENURE WITH THE UNIVERSITY. 364883 310000 1215 THE FISHER CENTER FOUNDATION INFORMATION PROGRAM:OUR INFORMATION PROGRAM PROMOTES DISEASE AWARENESS, EDUCATION AND RESOURCES FOR PEOPLE WITH ALZHEIMER'S, THEIR FAMILY, FRIENDS AND CAREGIVERS. INFORMATION IS DISPERSED THROUGH SOCIAL NETWORKS, ELECTRONIC AND PHYSICAL MAILINGS, AND THE INTERNET. OUR WEBSITE, ALZINFO.ORG, IS UPDATED REGULARLY TO PROVIDE COMPREHENSIVE DATA ABOUT ALZHEIMER'S DISEASE, RECENT RESEARCH STUDIES AND FINDINGS, TREATMENT, AND DISEASE MANAGEMENT. THE SITE HAS OVER 434,000 UNIQUE VISITORS A YEAR. OUR MAGAZINE, PRESERVING YOUR MEMORY, CIRCULATES OVER 50,000 COPIES PER ISSUE AND CONTINUES TO WIN AWARDS BASED ON ITS EDITORIAL CONTENT AS IT ADDRESSES READERS' CONCERNS OVER DIAGNOSIS AND PROGRESSION OF ALZHEIMER'S DISEASE. OUR FREE BI-WEEKLY E-NEWSLETTER, ALZHEIMER'S RESEARCH NEWS YOU CAN USE, CONTINUES TO BE THE MOST REVIEWED ALZHEIMER'S AND DEMENTIA NEWSLETTER ON THE INTERNET WITH OVER 10,000 SUBSCRIBERS. OUR SOCIAL MEDIA PRESENCE CONTINUES TO GROW, DRIVING FOLLOWERS TO OUR WEBSITE TO SEEK OUT OTHER INFORMATION PROGRAM MATERIALS. 50000 50000 0 A GRANT WAS GIVEN TO A EUROPEAN CENTER OF RESEARCH, CARE AND EDUCATION ON GENETIC DISEASES TO INVESTIGATE WHETHER STRUCTURE OF AMYLOID PROTEINS ARE CHANGED PARTICULARLY IF PROTEINS AGGREGATES, WHICH ARE TOXIC FOR SYNAPSES, ARE DECREASED. IN THIS HYPOTHESIS, MASITINIB MAYDECREASE PROTEASE RELEASE BY MAST CELLS, WHICH MAY BE RESPONSIBLE FOR GENERATION OF PROTEINS AGGREGATE, AND TEST WHETHER MASITINIB IS ABLE TO BLOCK LESIONS SPREADING AFTER PRIONS LIKE PROTEINS INOCULATION. THIS PROJECT WILL REVEAL ROLE OF MAST CELL AND KINASES IN THE PATHOPHYSIOLOGY OF ALZHEIMER DISEASE. A BETTER UNDERSTANDING OF ITS MECHANISMS MAY DEFINE THE BEST STRATEGY TO IMPROVE ALZHEIMER'S DISEASE. 677826 622943 1215 11014822 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 9 0 7 1 0 0 0 0 0 0 0 0 0 0 0 0 X 10 10 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 UT IL MI NJ NY NC PA VA WI CA MD X X X LUCRETIA HOLDEN 2129151328 750 LEXINGTON AVENUE NEW YORK NY 10022 BARRY R SLOANE CHAIRMAN/TREASURER 5.00 X X 0 0 0 MARTIN EDELMAN VICE CHAIRMAN 0.75 X X 0 0 0 DAVID HW TURNER SECRET- ARY (THRU DEC 2022), VICE CHAIRMAN 0.75 X X 0 0 0 HADLEY M FISHER TRUSTEE (THRU DEC 2022), SECRETARY 0.75 X X 0 0 0 DR MANNY ALVAREZ TRUSTEE 0.75 X 0 0 0 GERRY BYRNE TRUSTEE 0.50 X 0 0 0 BETSY GOTBAUM TRUSTEE 0.25 X 0 0 0 JAMES L NEDERLANDER TRUSTEE 0.25 X 0 0 0 RICHARD J SALEM TRUSTEE 1.00 X 0 0 0 DR MOSHE SHIKE TRUSTEE 0.25 X 0 0 0 LUCRETIA HOLDEN EXECUTIVE DIRECTOR 40.00 X 280901 0 33537 CHRISTINA HALL SENIOR DIRECTOR, STRATEGIC DEV. 40.00 X 102741 0 9834 383642 0 43371 2 0 1 0 CORE STAFFING SERVICES INC 463 SEVENTH AVE STE 1800 NEW YORK NY 10018 TEMPORARY STAFFING 365240 THE STAYWELL COMPANY LLC PO BOX 90477 CHICAGO IL 606960477 PUBLISHING SERVICES 263853 ELITE ACCOUNTING SERVICES LLC 500 MAMARONECK AVE HARRISON NY 10528 BOOKKEEPING SERVICES 114187 3 180304 7204379 139917 7384683 MAGAZINE SUBSCRIPTIONS 900099 1215 1215 1215 497623 497623 9918719 10718232 -799513 -799513 -799513 7084008 1215 0 -301890 10072943 10072943 50000 50000 314438 204385 62888 47165 505406 236123 83605 185678 21989 9689 3527 8773 25072 11835 4170 9067 54661 29133 9722 15806 34381 34381 150539 150539 172538 172538 279916 42988 79164 157764 155575 147461 8114 80921 37622 12527 30772 36292 27876 8416 16246 16246 6617 6617 4402 4402 17768 17768 PRINTING AND PUBLISHING 317234 317234 CREDIT CARD PROCESSING 62860 62860 DUES & SUBSCRIPTIONS 54585 2870 39154 12561 12434383 11014822 935445 484116 4661576 2553764 7021888 2191200 1507752 958539 5182 5154 26851 40759 36807 16664 12158 20143 27567024 24089136 283958 0 53615 40802431 30196268 143669 156698 10192274 9565217 10335943 9721915 X 30267901 20294049 198587 180304 30466488 20474353 40802431 30196268 X -5350375 -5627186 1000000 -14574 X X 0 1 X 1 0 X 5365421 6868429 7444215 8297600 7384683 35360348 5365421 6868429 7444215 8297600 7384683 35360348 883292 34477056 324830 480283 383515 422331 497623 2108582 670 3000 385 2643 0 6698 37475628 4311 0.92000 0.90950 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2018 AMOUNT: $ 670. 2019 AMOUNT: $ 3,000. 2020 AMOUNT: $ 385. 2021 AMOUNT: $ 2,643. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 36807 16664 20143 20143 X 1420815 -5627186 136531 -5490655 6911470 172538 172538 7084008 12412950 136531 14574 151105 12261845 172538 172538 12434383 PART X, LINE 2: THE FOUNDATION RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT THE FOUNDATION HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. THE FOUNDATION IS NO LONGER SUBJECT TO EXAMINATIONS BY THE APPLICABLE TAXING JURISDICTIONS FOR TAX YEARS PRIOR TO 2019. PART XII, LINE 2D - OTHER ADJUSTMENTS: WRITE-OFF OF UNCOLLECTABLE PLEDGES 14,574. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANT TO RECIPIENT LOCATED IN THE REGION 50000 0 0 0 0 0 0 50000 0 50000 EUROPE (INCLUDING ICELAND & GREENLAND) ALZHEIMER'S RESEARCH 50000 CHECK 0 1 0 0 0 0 0 0 0 PART I, LINE 2: A SINGLE GRANT WAS GIVEN TO A RESEARCH INSTITUTE IN EUROPE FOR PROGRAM-RELATED RESEARCH. THE GRANTEE ORGANIZATION PROVIDED THE ORGANIZATION WITH AN INTERIM SIX MONTH REPORT ON THE PROGRESS OF THEIR INVESTIGATIONS, AS WELL AS A FINAL REPORT AT THE END OF THE AGREEMENT. PART I, LINE 3: THE ORGANIZATION USES THE ACCRUAL METHOD OF ACCOUNTING TO ACCOUNT FOR ITS FOREIGN EXPENDITURES. PART III ACCOUNTING METHOD: 1 THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501(C)(3) 9762943 0 TO FUND ALZHEIMER'S DISEASE RESEARCH. SEE PART IV FOR DETAILS. NEW YORK UNIVERSITY ONE PARK AVENUE NEW YORK NY 10016 135562308 501(C)(3) 300000 0 TO FUND ALZHEIMER'S DISEASE RESEARCH. 2 0 PART I, LINE 2: THE ORGANIZATION MONITORS THE USE OF GRANT FUNDS IN THE U.S. BY RECEIVING PERIODIC PROGRESS REPORTS ON THE RESEARCH CONDUCTED AND ANY FINDINGS PUBLISHED AS A RESULT OF THE FUNDING. THE GRANT DECISIONS ARE MADE UNDER THE SOLE AND ABSOLUTE DISCRETION OF THE BOARD PURSUANT TO A MAJORITY VOTE. A SCIENCE ADVISORY BOARD COMPRISED OF MEDICAL AND SCIENTIFIC EXPERTS IN THE FIELD OF ALZHEIMER'S DISEASE AND RELATED DISEASES ADVISES AND ASSISTS THE ORGANIZATION IN CONNECTION WITH FUNDING GRANT REQUESTS. ADDITIONALLY, NEW YORK UNIVERSITY PREPARES A RESEARCH PRESENTATION DURING AT LEAST ONE OF THE BOARD MEETINGS DURING THE CALENDAR YEAR. NYU ALSO PROVIDES THE FOUNDATION WITH A WRITTEN REPORT. FORM 990, SCHEDULE I, PART II, COLUMN (H): PURPOSES OF GRANTS TO THE ROCKEFELLER UNIVERSITY: THE ROCKEFELLER UNIVERSITY FISHER CENTER FOR ALZHEIMER'S RESEARCH LAB: THIS GRANT FUNDS NEUROLOGICAL RESEARCH INTO THE CAUSE(S) OF ALZHEIMER'S, AND POTENTIAL NEW PHARMACOLOGICAL TREATMENT OPTIONS, AND TO SUPPORT PROFESSORSHIPS TO CONDUCT RESEARCH ACTIVITIES. THE ZACHARY AND ELIZABETH M. FISHER PROFESSORSHIP IN ALZHEIMER'S AND NEURODEGENERATIVE DISEASE: THIS GRANT FUNDS A PROFESSORSHIP NAMED FOR THE ORGANIZATION'S FOUNDERS THAT ADVANCES THE UNDERSTANDING OF AND TREATMENT FOR ALZHEIMER'S AND OTHER DEBILITATING DISEASES. THIS PROFESSORSHIP IS CURRENTLY HELD BY DR. SIDNEY STRICKLAND WHO HEADS THE UNIVERSITY'S PATRICIA AND JOHN ROSENWALD LABORATORY OF NEUROBIOLOGY AND GENETICS. THE ROCKEFELLER UNIVERSITY GREENGARD PROFESSORSHIP IN NEUROSCIENCE: THIS GRANT HONORS NOBEL LAUREATE DR. PAUL GREENGARD AND THE NEARLY 25 YEARS HE SPENT AS DIRECTOR FOR THE ZACHARY AND ELIZABETH M. FISHER CENTER ON ALZHEIMER'S RESEARCH LAB AT THE ROCKEFELLER UNIVERSITY BEFORE HIS DEATH IN 2019. THE NAMED CHAIR WILL BE SOMEONE WHO HONORS GREENGARD'S LEGACY IN CONDUCTING RESEARCH TO FIND A CURE FOR ALZHEIMER'S DISEASE. X X X 0 0 0 0 0 0 0 1 0 LUCRETIA HOLDEN EXECUTIVE DIRECTOR 210477 0 70000 0 424 0 17350 0 16187 0 314438 0 0 0 PART I, LINE 7 THE ORGANIZATON PAID DISCRETIONARY BOARD-APPROVED BONUSES IN 2022. THE AMOUNTS ARE REPORTED IN PART II, COLUMN B(II). X 15 139917 AVG SELLING PRICE 0 0 1 0 PART I, COLUMN (B): THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS IN COLUMN (B). FORM 990, PART VI, SECTION B, LINE 11B THE 990 IS INITIALLY REVIEWED BY MEMBERS OF THE AUDIT COMMITTEE THAT CONSISTS OF 3 INDEPENDENT TRUSTEES. A COPY IS THEN FORWARDED ELECTRONICALLY TO ALL BOARD MEMBERS AND RELEVANT MANAGEMENT PERSONNEL FOR THEIR REVIEW AND COMMENT. ANY REQUIRED REVISIONS ARE MADE AND THE REVISED 990 IS RESUBMITTED TO ALL BOARD MEMBERS FOR FINAL REVIEW BEFORE FILING. FORM 990, PART VI, SECTION B, LINE 12C THE FOUNDATION HAS A CONFLICT OF INTEREST POLICY WHICH IS ANNUALLY MONITORED REQUIRING ALL TRUSTEES TO DISCLOSE ANY POSSIBLE CONFLICT OF INTEREST VIA EMAIL RESPONSE TO THE EXECUTIVE DIRECTOR. THE FOUNDATION REQUIRES THAT ALL TRUSTEES, OFFICERS, KEY EMPLOYEES AND STAFF PERSONNEL PROMPTLY AND FULLY DISCLOSE ALL MATERIAL FACTS OF ANY ACTUAL OR POTENTIAL CONFLICT OF INTEREST THAT MAY EXIST AT THE TIME THE TRUSTEE IS APPOINTED OR STAFF PERSONNEL IS HIRED, OR AS THEY MAY ARISE WHILE THE TRUSTEE IS SERVING ON THE BOARD OR THE STAFF PERSONNEL IS EMPLOYED BY THE FOUNDATION. SUCH DISCLOSURES INVOLVING A TRANSACTION, ARRANGEMENT OR DECISION BEING CONSIDERED BY THE BOARD ARE MADE KNOWN TO ALL TRUSTEES. THE BOARD THEN DETERMINES WHETHER A CONFLICT OF INTEREST EXISTS WITH THE INTERESTED PARTY ABSTAINING FROM THE DECISION. IF IT IS DETERMINED THAT A CONFLICT EXISTS, THEN THE BOARD VOTES ON THE TRANSACTION BUT WITH THE INTERESTED PARTY RECUSING HIMSELF FROM THE DISCUSSION AND VOTE ON SAID MATTER. FORM 990, PART VI, SECTION B, LINE 15A THE FOUNDATION HAS A COMPENSATION COMMITTEE CONSISTING OF THE CHAIRMAN/TREASURER AND VICE CHAIRMAN MANDATED BY ITS CHARTER TO REVIEW THE EXECUTIVE AND OTHER KEY EMPLOYEE PERFORMANCE APPRAISAL CONSISTENT WITH THE GOALS AND OBJECTIVES OF THE FOUNDATION. AT LEAST ONCE A YEAR, THE COMMITTEE IS MANDATED BY ITS CHARTER TO REVIEW EXECUTIVE DIRECTOR'S PERFORMANCE CONSISTENT WITH THE GOALS AND OBJECTIVES OF THE FOUNDATION AS DETERMINED BY THE BOARD OF TRUSTEES, AND TO DETERMINE AN APPROPRIATE LEVEL OF COMPENSATION IN LIGHT OF THIS PERFORMANCE REVIEW AND USING OTHER SUBSTANTIATING DATA SURVEYS ON CURRENT COMPENSATION RATES FOR SIMILAR POSITIONS IN OTHER COMPARABLE NONPROFITS IN THE NEW YORK CITY AREA. THE COMMITTEE'S DECISION IS DOCUMENTED IN A CONTEMPORANEOUSLY WRITTEN FORMAT (COMPENSATION COMMITTEE MINUTES) INDICATING THE DATE OF THE MEETING, THE MEMBERS PRESENT, AND THE COMPARABLE DATA USED TO MAKE THE DECISION. THE COMPENSATION REVIEW PROCESS FOR THE EXECUTIVE DIRECTOR WAS LAST UNDERTAKEN IN NOVEMBER 2022. FORM 990, PART VI, SECTION C, LINE 19 THE FOUNDATION MAKES ITS FORM 990 AND AUDITED FINANCIAL STATEMENTS AVAILABLE FOR PUBLIC INSPECTION BY POSTING ON THEIR WEBSITE. IN ADDITION, THE ORGANIZATION'S GOVERNING DOCUMENTS, AUDITED FINANCIAL STATEMENTS, AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. FORM 990, PART XI, LINE 9: WRITE-OFF OF UNCOLLECTABLE PLEDGES -14,574. FORM 990, PART XII, LINE 2C: THE FOUNDATION HAS AN AUDIT COMMITTEE THAT IS RESPONSIBLE FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND THE SELECTION OF AN INDEPENDENT ACCOUNTANT. THE PROCESS HAS NOT CHANGED FROM THE PREVIOUS YEAR. FORM 990, PART XI, LINE 8: DURING 2022, THE FOUNDATION IDENTIFIED $1,000,000 OF GRANT EXPENSE - RESEARCH THAT WAS OVERSTATED IN 2021. THE NECESSARY CORRECTIVE ADJUSTMENT RESULTED IN A DECREASE IN GRANTS PAYABLE AT DECEMBER 31, 2021 AND AN INCREASE IN NET ASSETS WITHOUT DONOR RESTRICTIONS AS OF DECEMBER 31, 2021.